Details
Stereochemistry | ACHIRAL |
Molecular Formula | C28H16ClF6N5O |
Molecular Weight | 587.903 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C1=CC(=CC(CN2N=NC(=C2C3=CC=NC=C3)C4=NC=CC=C4C(=O)C5=CC=CC=C5Cl)=C1)C(F)(F)F
InChI
InChIKey=CAVRKWRKTNINFF-UHFFFAOYSA-N
InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2
Molecular Formula | C28H16ClF6N5O |
Molecular Weight | 587.903 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Tradipitant is a neurokinin 1 receptor antagonist. The dose of 50 mg of tradipitant given orally for 4 weeks was not superior to placebo in reducing itch intensity in patients with atopic dermatitis. However, in a subsequent study, in which a higher dose (85 mg) was administered for 8 weeks, significant antipruritic effect compared with placebo was recorded. Tradipitant is in phase III clinical trial for the treatment of atopic dermatitis and gastroparesis. Vanda Pharmaceuticals plans a phase III trial in Motion Sickness in 2019.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/31190215 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:36:21 GMT 2025
by
admin
on
Mon Mar 31 18:36:21 GMT 2025
|
Record UNII |
NY0COC51FI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78284
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000021772
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
NY0COC51FI
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
CD-17
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
DTXSID801045805
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
Tradipitant
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
DB12580
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
9916461
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL3544984
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
C152707
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
9996
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY | |||
|
622370-35-8
Created by
admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
ANTAGONIST
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Entered into Phase II clinical trials for social anxiety disorder and alcoholism treatment. It was found ineffective against anxiety disorder. The results of the alcoholism treatment trial
have not been published.
|